Experimental drug cocktail aims to boost liver cancer fight

NCT ID NCT07365839

Not yet recruiting Disease control Sponsor: Virginia Commonwealth University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether adding the immunotherapy drugs cemiplimab (with or without fianlimab) after a standard liver cancer procedure called Y90 radioembolization can help control hepatocellular carcinoma. About 20 adults with liver cancer will be randomly assigned to one of two drug regimens. The main goal is to see how long the cancer stays under control, while also checking for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cemiplimab (Libtayo) and fianlimab
What this could lead to: If successful, this could point toward a new combination treatment for liver cancer that may help control the disease longer.
What could go wrong: This is a very early, small pilot study with only 20 participants. The drugs may cause serious side effects, and results may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Virginia Commonwealth University

Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.